This trial prospectively recruited men with prostate cancer from fourteen centers (seven open and seven robot-assisted surgery centers). Data on patient-reported erectile-function was collected before, three, twelve and twenty-four months after surgery. Neurovascular bundle preservation was subjectively reported by the respective urologists, while rates of positive surgical margins were defined by pathologists. Lastly, biochemical recurrence rate was measured at three, twelve, and twenty-four months. Despite long-term follow up, high completion rates (>90%) were present.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In conclusion, tumor characteristics can be used as a distinguishing factor when assessing erectile-function recovery and oncologic outcomes among the two surgical techniques common to the prostatectomy. This study ultimately suggests the improvement of surgery plane irrespective of technique used.
Presented By: Prasanna Sooriakumaran
Authors: Prasanna Sooriakumaran*, Oxford, United Kingdom; Gio Pini, Milan, Italy; Tommy Nyberg, Maryam Derogar, Stefan Carlsson, Stockholm, Sweden; Johan Stranne, Gothenburg, Sweden; Anders Bjartell, Lund, Sweden; Jonas Hugosson, Gothenburg, Sweden; Gunnar Steineck, Peter Wiklund, Stockholm, Sweden
Written By: Rita Derderian, University of California, Irvine for UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA